Moderna plans to increase the production of its vaccines with the expectation of export deliveries

According to the publication, the company is expanding the production of its vaccine outside the United States.

The American company Moderna is building two new production lines, the launch of which will allow it to increase the production of coronavirus vaccines by 50%, currently carried out at the company’s facility in Norwood, a suburb of Boston (Massachusetts). This was reported by The Wall Street Journal on Monday, citing a statement by the head of Moderna, Stephane Bancel.

The head of the company noted that the increase in production of the drug will not only meet the needs for it in the United States itself but also make it possible in the future to export this vaccine to other countries.

“We plan and hope that as soon as the United States has sufficient [stocks] of the vaccine, we will be allowed to export it so that we can help as many countries around the world as possible,” the publication quotes Bancel as saying.

The first of the production lines under construction is planned to be launched in the coming autumn, the second – in early 2022. The company, the newspaper writes, is also expanding production of its vaccine outside the United States, which – with the assistance of its partners-will allow it to bring the production of the drug to about 3 billion doses in 2022, compared to 1 billion doses planned for production this year.

If you have found a spelling error, please, notify us by selecting that text and pressing Ctrl+Enter.

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Author: Steve Cowan
Graduated From Princeton University. He has been at the Free Press since October 2014. Previously worked as a regional entertainment editor.
Function: Chief-Editor
Steve Cowan

Spelling error report

The following text will be sent to our editors:

30 number 0.274965 time